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Introduction.-e hepatic steatosis of the nonalcoholic origin or NAFLD is increasing at present, particularly inWestern countries,
parallel to the increase in obesity, constituting one of the most prevalent hepatic processes in the Western society. Melatonin has
been successfully tested in experimental models in mice as a drug capable of reversing steatosis. -e effect of melatonin on fat
metabolism can be summarized as a decrease in lipid peroxidation and a decrease in oxidative stress, biochemical phenomena
intimately related to fat deposition in the hepatocyte. -ere are hardly any studies in large animals. Objective. In this study, we
investigate the effects of melatonin administered orally at a dose of 10mg/kg/day to reverse established hepatic steatosis induced
by a special diet in a porcine animal model. Materials and Methods. We analyze the parameters of oxidative stress: malon-
dialdehyde (MDA), 4-hydroxyalkenals (4-HDA), and carbonyls, degree of fat infiltration (analyzed by direct vision by a pa-
thologist and by means of a computer program of image treatment), and serological parameters of lipid metabolism and hepatic
damage. -ese parameters were analyzed in animals to which hepatic steatosis was induced by means of dietary modifications.
Results. We have not been able to demonstrate globally a beneficial effect of melatonin in the improvement or reversal of liver
steatosis once established, induced by diet in a porcine animal model. However, we have found several signs of improvement at the
histological level, at the level of lipid metabolism, and at the level of oxidative stress parameters. We have verified in our study that,
in the histological analysis of the liver sample by means of the program image treatment (free of subjectivity) of the animals that
continue with the diet, those that consume melatonin do not increase steatosis as much as those that do not consume it sig-
nificantly (p � 0.002). Regarding the parameters of oxidative stress, MDA modifies in a significant manner within the group of
animals that continue with the diet and take melatonin (p � 0.004). As for lipid metabolism, animals that maintain the steatotic
diet and take melatonin lower total and LDL cholesterol levels and increase HDL levels, although these results do not acquire
statistical significance. Conclusions. In this study, it has not been possible to demonstrate a beneficial effect of melatonin in the
improvement or reversal of liver steatosis once established and induced by diet in the porcine model. It is true that signs of
improvement have been found at the histological level, at the level of lipid metabolism, and at the level of oxidative stress
phenomena, when comparing animals with established steatosis that are treated withmelatonin with those who do not take it.-is
work is the first study conducted in a large animal model in which the effect of melatonin is studied as a treatment in the reversal of
established hepatic steatosis.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is characterized by
the accumulation of fatty acids, triglycerides, and cholesterol
in the cytoplasm of the hepatocyte. It occurs in subjects who
do not drink alcohol or drink moderately (<20 g/day) and is
considered as the expression in the liver of a complex
syndrome called “metabolic syndrome.” NAFLD includes
two clinical entities: nonalcoholic fatty liver (NAFL), which
refers to the presence of hepatic steatosis without evidence of
hepatocellular damage or fibrosis, and nonalcoholic stea-
tohepatitis (NASH), which is the presence of hepatic stea-
tosis that is associated with inflammation and liver damage
with or without fibrosis. NASH may progress to cirrhosis,
liver failure, and hepatocarcinoma [1].
-e prevalence of NAFLD is not well known and is
probably underestimated. -is is because most patients
remain asymptomatic or have discrete biological alterations,
the absence of precise serological markers, and the need for
liver biopsy for definitive diagnosis. However, we know that
steatosis is one of the most prevalent liver diseases in the
Western world, linked to the increase in obesity and met-
abolic syndrome, and varies widely depending on the
population studied. Two Japanese studies [2, 3] published an
incidence in the general population of 31 and 86 cases,
respectively, of suspected NAFLD per 1000 persons/year. In
severely obese patients undergoing bariatric surgery, the
prevalence of NAFLD may exceed 90% and up to 5% may
have cirrhosis.
-e treatment of hepatic steatosis once established is
achieved primarily through dietary restrictions and lifestyle
changes [4–7]. Drugs used in the treatment of metabolic
syndrome (antidiabetics, statins, etc.) have also been used
[8]. Recently, the efficacy of various antioxidant agents, such
as vitamin E and melatonin [9–11], has been demonstrated
in the treatment of hepatic steatosis. -ere is currently no
specific harmless and effective treatment for hepatic
steatosis.
Melatonin is a natural hormone synthesized by the pi-
neal gland in animals. Melatonin synthesis is not found
exclusively in the pineal gland, as its secretion has been
described in numerous peripheral organs such as the retina,
bone marrow, skin, and gastrointestinal tract and in some
cells such as lymphocytes and platelets [12, 13].
One of the main properties of melatonin is its powerful
antioxidant effect [12], which is attributed to its ability to
neutralize free radicals and its indirect detoxifying action by
stimulating antioxidant enzymes [14]. It has been proven
that melatonin supplements could protect against some
diseases such as atherosclerosis, cancer, and Alzheimer’s
disease. At the level of hepatic metabolism, melatonin has
been tested as a drug to prevent the process of ischemia-
reperfusion [15] and also as a treatment of liver damage by
toxins such as alcohol, carbon tetrachloride, aflatoxin, or
chemotherapy agents [16–19].
Melatonin has been shown to be beneficial in the
treatment and prevention of NAFLD in murine experi-
mental models. Experimental studies have been carried out
in rodents, the majority with the intention of preventing
diet-induced hepatic steatosis, observing a decrease in blood
lipids, an improvement in hepatic enzymes, and a decrease
in oxidative stress parameters, as well as an improvement in
histology [20–25]. -ere are hardly any studies in large or
small animals that prove this effect. In humans, studies have
been carried out that demonstrate the lipid lowering and
cytoprotective capacity of melatonin in hepatic steatosis
once established, although it is true that there are hardly any
studies that demonstrate histological improvement [26–29].
Our working hypothesis is based on the fact that mel-
atonin is an effective treatment to reverse established and
induced hepatic steatosis by means of a special diet in a
porcine animal model, as well as in the murine model. -e
aim of our study is to assess the effect of melatonin ad-
ministered orally on lipidmetabolism, hepatic histology, and
oxidative stress parameters.
2. Material and Methods
2.1.Model and Sample: AnExperimental Animal. We use the
great English white pig as an experimental animal. -is
model was chosen as such because it is consistent with the
hepatic physiology of the human.-e animals were obtained
from a breeding farm for animal experimentation, which
were free of diseases or parasites and with an approximate
weight of 45 kg and an approximate age of 6 months. All
animals that did not meet a minimum weight (30 kg) or that
showed signs of diseases (diarrhoea, adynamia, dermatosis,
and abnormal behaviour) were excluded from the experi-
ment. -e animals were kept in cages, shared by 3 or 4
animals, and provided with feeders and water.-e study was
approved by the Advisory Ethics Commission for Animal
Experimentation of the University of Zaragoza.
2.2. ExperimentalDesignandStudyGroups. -e induction of
steatosis was carried out by means of a special diet, without
using any pharmacological agent. Its main characteristics
were as follows: high content in saturated fat (25%), defi-
ciency in methionine and choline, and supplemented with
2% cholesterol plus 0.5% sodium cholate. -e animals be-
longing to study groups 1 and 3 received melatonin doses of
10mg/kg/day orally for 4 weeks. -e drug was acquired in
powder form, which was encapsulated in a sucrose excipient.
It was administered in a single dose by means of capsules
that were ingested at the same time as the diet described
above, mixing the drug with part of the diet in such a way as
to ensure complete intake.
A control group consisted of 6 animals; healthy animals
without steatosis underwent a normal nonsteatosis diet and
underwent a single surgical intervention for the purpose of
obtaining samples, whose values served as a reference. 31
animals were part of the study. For 3 months, they were on
an original diet of our group specially designed to produce
steatosis, at the end of which, they underwent an open
biopsy (to obtain sufficient samples). After the surgical
intervention, the animals were assigned to 4 study groups:
group 1 (N� 12): animals that maintained a steatotic diet for
1 more month and received concomitant treatment during
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this month with melatonin (10mg/kg/day); group 2 (N� 9):
animals that maintained a steatotic diet for one more month
and received no drug; group 3 (N� 5): animals that did not
continue with the steatotic diet but received melatonin
treatment for one month at the same dose; group 4 (N� 5):
animals that did not continue with the steatotic diet and did
not receive any drug. After this time, the animals underwent
a second surgical intervention to obtain the same samples of
liver tissue, blood, and serum. After this second operation,
the animals were slaughtered.
In each surgical intervention, a minilaparotomy was
performed to observe the macroscopic characteristics of the
liver and to take a sample of hepatic tissue from segment IV.
-is sample was divided into two parts: one of them was kept
in formaldehyde for anatomopathological study. Another
sample was frozen and preserved in liquid nitrogen to obtain
oxidative stress parameters: MDA and carbonyls. During the
intervention, a sample of 20ml of venous blood extracted from
the portal vein or the vena cava was also obtained. -e blood
was centrifuged at 3000 rpm for 3min to obtain serum.
Biochemical parameters were obtained from the blood sample.
2.3. Induction of Hepatic Steatosis. In the experimental
porcine model, hepatic steatosis can be induced by means of
a specially developed and proven diet that resembles the
induction of steatosis in humans. -is is without the need to
use drugs or toxic products. -e induction of steatosis was
carried out through a special diet whose main characteristics
were as follows:
(i) High saturated fat content (25%)
(ii) Deficient in methionine (<1/4 of the needs) and
choline (1/6 of the needs)
(iii) Supplemented with 2% cholesterol and 0.5% so-
dium cholate.-e following table shows its
composition
2.4. Histological Analysis of Liver Biopsy. To determine the
degree of hepatic steatosis, we used two methods. Method 1 is
a conventional semiquantitative analysis in which the pa-
thologist estimates the percentage of steatosis under direct
vision (HEX ×1000) of each sample expressed in %. Method 2
is a method of quantification via computer-assisted analysis
consisting of an estimate of the area of computer-assisted
steatosis of samples obtained and previously selected.
-e program measures the degree of steatosis by ana-
lyzing tonalities from photographs taken of each sample of
hepatic tissue, without areas occupied by vessels and other
structures. We use a specific software assisted by Matlab®,created by the research group itself to perform a digital
analysis of the biopsy samples. It has three fundamental
functions:
(i) Cal-estea.m: it is the main function that performs
the calculation of steatosis
(ii) Filter-m: it is the function of the gray filter, which
allows the program to be adapted to the wide range
of shades that can be presented to us in the sample
(iii) Region-m: it is the function that eliminates regions
that do not correspond to fat (for example, veins
with white tones)
2.5. Measurement of Oxidative Stress Parameters: MDA and
Carbonyls. -e concentration of MDA+4-hydroxyalkenals
(4-HDA) was determined by a colourimetric method based
on the reaction of a chromogenic reagent, N-methyl-2-
phenylindole, with MDA or with 4-HDA, at a temperature
of 45°C. -e condensation of one MDA or 4-HDA molecule
with two molecules of N-methyl-2-phenylindole produces a
stable chromophore which, in the presence of meth-
anesulfonic acid, has a maximum absorbance at 586 nm [30].
In order to evaluate the oxidative damage to the proteins
of the homogenized ones, the determination of the carbonyl
remains of the proteins was used. -is method is based on
the reaction of the carbonyl remains of proteins with
dinitrophenylhydrazine (DNPH), forming a derivative that
is quantified by measuring its absorbance in the range
360–390 nm. During the procedure, trichloroacetic acid
(TCA) is used for the precipitation of proteins, washes for
the removal of excess DNPH that has not reacted with
carbonyl residues, and guanidine to redissolve the proteins
in order to facilitate spectrophotometer readings.
From the absorbance obtained, the concentration of
carbonyl moieties was calculated using the Beer–Lambert
law and the molar absorption coefficient of DNPH
(Ɛ� 22,000 M-1× cm−1). Finally, after the determination of
the total proteins, the results were expressed in nmol of
carbonyl moieties/mg of total proteins.
-e laboratory equipment included a spectrophotometer
with disposable plastic cuvettes to measure the visible range
and quartz cuvettes to measure in the ultraviolet (UV) range.
2.6. Measurement of Biochemical Parameters. -e mea-
surement of serological parameters of hepatic function
(aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), gamma-glutamyl transferase (GGT), alkaline
phosphatase (FA), and bilirubin (B)) and plasma lipid
concentration (total cholesterol, HDL cholesterol, and LDL
cholesterol) was performed by automatic processors for
automatic reading of concentrations of liver lipids and
enzymes.
2.7. Variables to Be Studied. -e following variables were
studied: the weight of the animal, steatosis reached, blood
lipids (triglycerides (TG), total cholesterol, HDL cholesterol,
and LDL cholesterol), hepatic enzymes (aspartate amino-
transferase (AST), alanine aminotransferase (ALT), gamma-
glutamyl transferase (GGT), alkaline-FA phosphatase, and
bilirubin), parameters of oxidative stress (MDA and car-
bonyls), and histology (degree of fat infiltration).
2.8. Statistic Analysis. To analyze the relationship between
the variables of a study, a bivariate analysis is carried out. To
study the linear relationship between two quantitative
variables, the Pearson or Spearman correlation coefficient is
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used. -e correlation coefficient can take values between −1
and 1, indicating the zero correlation between the variables
under study. To evaluate the differences between the first
biopsy or pre and the second biopsy or post, in relation to the
quantitative variables of the study, means comparison
methods are used for related samples. Wilcoxon is used
when the variable does not follow the normal distribution,
and Student’s t-test is used when there is normality.
To quantify the difference between both time periods, we
calculate the percentage of change. Positive results will in-
dicate increased values in the postbiopsy and negative results
will indicate decreased values.
3. Results
3.1. Steatosis Reached. -e total of 31 (100%) animals in the
study group presented significant hepatic steatosis in the first
biopsy, moderate (steatosis 30–59%) and severe (steatosis
>60%) after being on a special diet for 3 months, both in the
measurement made by the pathologist and in the mea-
surement made by the computer program.
Figure 1 shows the average degree of steatosis of the
animals for each of the animals according to pathologist
analysis and digital image analysis. -ere are no statistically
significant differences in the average steatosis reached per
group.
It is observed that the degree of steatosis according to the
digital analysis provides in all cases average values lower
than those provided according to an analysis by a pathol-
ogist. On average, the degree of steatosis according to a
pathologist scores 40.68 (DE� 14.66) more than that
according to the digital analysis at the premoment.
Figure 2 shows the optical microscopy image of the
animal with the highest percentage of steatosis being seen by
a pathologist (95% of steatosis) and the optical microscopy
image of the animal with the lowest degree of steatosis being
seen under direct vision by a pathologist (40% of steatosis).
3.2. Weight. In all groups, there was an increase in average
weight between the two time periods evaluated, as shown in
Figure 3, this increase being statistically significant in groups
1, 3, and 4 (p � 0.03, p � 0.043, and p � 0.043, respectively).
In all groups, the percentage change (% difference in
weight at the end of the study with respect to the initial





3.3. Biochemical Variables: Triglycerides, Total Cholesterol,
HDL, LDL, AST, ALT, GGT, and FA. Figures 4–7 show the
mean prevalue and postvalue of each of the parameters
evaluated for each of the study groups.
3.3.1. Group 1. In group 1 (the group that continued with
the steatotic diet and was treated with melatonin), no pa-
rameter shows statistically significant differences (p> 0.05)
before and after treatment.
3.3.2. Group 2. In group 2 (the group that continued with
the steatotic diet and was not treated with melatonin), the
average ASTdecreased significantly (p � 0.008), going from
75.11 UI/L (DE� 47.29) to 32.67 UI/L (DE� 13.93); there is
also a significant decrease (p � 0.017) of the average B going
from 0.73 UI/L (DE� 0.83) to 0.22 (DE� 0.26).
3.3.3. Group 3. In group 3 (the group that discontinued the
diet and was treated with melatonin), the average values of
total cholesterol, HDL, LDL, GGT, and FA decreased at the
end of the study period in a statistically significant way,
compared with the values at the beginning (p � 0.043 in all
cases). However, we observe a significant increase in ALT
and AST (p � 0.043 and p � 0.042 respectively).
3.3.4. Group 4. In group 4 (the group that discontinued
the steatotic diet and was not treated with melatonin), the
average values of TG, total cholesterol, HDL, LDL, AST,
GGT, and FA also decreased at the end of the study
period, presenting significant differences between the two
study time periods (pre and post) (p � 0.043 in all cases).
However there is a significant increase in ALT
(p � 0.042).
3.4. Analysis of Hepatic Fat Infiltration. Figure 8 shows
graphically the degree of average steatosis by groups in the
two study time periods analyzed by the direct vision of the
pathologist.
A decrease in steatosis was observed in groups 3 and 4,
and an increase in steatosis in groups 1 and 2, with a sig-
nificant decrease in group 4 (p � 0.042), the animals that
discontinued their diet and were not treated with melatonin.
Figure 9 shows graphically the degree of average steatosis
by groups in the two study time periods digitally analyzed by
the image processing software.
-ere is a decrease in steatosis in groups 3 and 4, and
there is an increase in steatosis in groups 1 and 2. -is
increase in group 2 is statistically significant (p � 0.08), as is
the decrease in group 4 (p � 0.043).
-e degree of steatosis measured by the program
provides lower average values in relation to the degree of
steatosis measured by the pathologist. On average, the
degree of steatosis measured by the direct vision of the
pathologist [31] scores 40.68% more in the premoment and
36.87% more in the postmoment. In Figure 10, it is possible
to observe, in a graphical way, the average values of the
degree of steatosis of both measurements by groups for
both periods of study (pre and post) and how the same
tendency is observed for the two methods of measurement
employed.
Figure 11 shows the relationship between the percentage
of change obtained with the program and the percentage of
change obtained with the pathologist.
-e percentage of change of steatosis between the pre-
time and posttime of the follow-up of the subjects shows a
strong linear relationship between both methods, obtaining





























∗p = 0.043 ∗p = 0.043
Figure 3: Average pre-post weight (kg) by study groups. Group 1: animals that maintained a steatotic diet and received concomitant
treatment. Group 2: animals that maintained a steatotic diet and received no drug. Group 3: animals that did not continue with the steatotic

































Figure 1: Average steatosis reached by each of the animals, according to the pathologist and program.
(a) (b)
Figure 2: Optical microscopy image, HE 2x dyeing with 95% steatosis (a) and optical microscopy image, HE 2x dyeing with 40%
steatosis (b).
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a correlation coefficient of 0.767 with a level of significance
being lower than 0.001.
3.5.MDA. Figure 12 shows graphically the degree of average
MDA by groups in the two study periods.
In all study groups, there was a decrease in the average
value of MDA, being statistically significant in group 1
(p � 0.04), the subjects that continued the steatotic diet and
were given melatonin.
3.6. Carbonyls. Figure 13 shows graphically the average
carbonyl degree by groups in the two study periods.
In groups 2, 3, and 4, there is an average increase of
carbonyls, being only significant in group 4 (p � 0.028). -e
small average decrease in group 1 (subjects that continue on
a diet and are treated with melatonin) does not have sta-
tistical significance, as in the case of MDA.
4. Discussion
NAFLD is one of the most prevalent hepatic processes in the
Western society and one of the major causes of liver failure
in the Western world. Usually associated with, but not
exclusively to, obesity and the metabolic syndrome, it could
lead to a real epidemic in the future. Numerous authors have
shown that the reduction of excess weight and the conse-
quent resistance to insulin can restore liver physiology and
histology [8,9]. But at the present time, there is no effective
pharmacological treatment of NAFLD that is not linked to a
lifestyle change, including weight loss. Many drugs, anti-
oxidants, hepatoprotectors, vitamin complexes, free radical
scavengers, etc. have been tested with the idea of either
avoiding the accumulation of lipids in the hepatocyte or
extracting lipids from cells, showing beneficial effects.
Although more studies are needed to define their use-
fulness in NAFLD [32–37], the discovery of a drug with these
properties could change the spectrum and impact of the
disease.
Melatonin, the universal hormone that is produced in
different concentrations, in almost all our anatomy, has been
studied as one of the possible solutions to the alteration of
lipid metabolism and fat deposition in the hepatocyte [12].
Experimental studies have shown an action of melatonin on
fat metabolism, which can be summarized as a decrease in
lipid peroxidation and a decrease in oxidative stress [13],
biochemical phenomena intimately related to the accumu-
lation of lipids in the hepatocyte. Other effects that have been
attributed to melatonin are as follows: stimulation of anti-
oxidant enzymes in hepatocytes, regulation of antioxidant
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Figure 4: Average values of the pre-post parameters for group 1.
TG� triglycerides, COL� total cholesterol, HDL�HDL choles-
terol, LDL� LDL cholesterol, B� bilirubin, AST�aspartate ami-
notransferase, ALT� alanine aminotransferase, GGT� gamma-

















































Figure 5: Average values of the pre-post parameters for group 2.
TG� triglycerides, COL� total cholesterol, HDL�HDL choles-
terol, LDL� LDL cholesterol, B� bilirubin, AST� aspartate ami-
notransferase, ALT� alanine aminotransferase, GGT� gamma-
glutamyl transferase, FA� alkaline phosphatase.
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radicals, stimulation of glutathione synthesis, increase in the
activity of other antioxidant molecules, decrease in the
generation of free radicals in mitochondria, decrease in the
expression of proteins that have an effect on the accumu-
lation of lipids in the hepatocyte cytoplasm, protection of cell
membranes against lipid peroxidation, and reduction of
proinflammatory factors responsible for the progression of
NAFLD to NASH.
Several experimental models have been described to
resemble humanNAFLD.-e ideal model would be one that
reflects both the histology and the physiopathology of the
disease in its different stages. Of course, this model should be
reproducible, reliable, simple, predictable, and economical.
Most of these models have been described in rodents. -ere
are few models of hepatic steatosis in large animals, and in
most of them, liver damage has been induced by the ad-
ministration of toxins such as alcohol [38,39].
In 2009, Lee et al. described, for the first time, a NASH
model in large animals produced by dietary manipulation
using Ossabaw miniature pigs [40]. -is model is not very
useful due to the restriction of the use of these animals. In
our work, we used an experimental model, the pig White-
Landrace, in which we reproduced steatosis. -is model is
original and sufficiently proven in previous studies of our
group and that has the particularity that only by means of
dietetic manipulation, without using drugs or toxics, con-
trolled and very high degrees of steatosis are achieved. We
have not found any model published thus far that induces,
without the use of substances harmful to the liver or an
aggressive diet (excess of polyunsaturated, fructose fats, or
the deficit of elements necessary for beta-oxidation such as
choline and methionine), a degree of macrovesicular stea-
tosis similar to ours, in such a short time and with minimal
repercussions on the physiology of the animal. Another
strength of our experimental model is that it allows us to
check liver damage and quantify steatosis by performing
liver biopsies before and after the development of steatosis;
in many murine models, this is not possible, and in humans,
no author performs them.
All steatogenic diets described induce an increase in the
weight of the animal. In our study, all animals increased in
weight after the introduction of the steatogenic diet.-e data
is consistent with the data found in the literature (Ossabaw
pigs). -e effects of melatonin were null on the weight of the
animal.
In order to explore the effect on the lipid metabolism of
melatonin, we studied lipid peroxidation (LPO) on the
polyunsaturated fatty acids of the hepatocyte (during the
process of accumulation of lipids in the hepatocyte, the
action of free radicals on the lipids takes place mainly on the



















































Figure 6: Average values of the pre-post parameters for group 3.
TG� triglycerides, COL� total cholesterol, HDL�HDL choles-
terol, LDL� LDL cholesterol, B� bilirubin, AST� aspartate ami-
notransferase, ALT� alanine aminotransferase, GGT� gamma-
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Figure 7: Average values of the pre-post parameters for group 4.
TG� triglycerides, COL� total cholesterol, HDL�HDL choles-
terol, LDL� LDL cholesterol, B� bilirubin, AST� aspartate ami-
notransferase, ALT� alanine aminotransferase, GGT� gamma-
glutamyl transferase, FA� alkaline phosphatase.
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peroxidation). -e final products of this process of LPO are
aldehydes, hydrocarbon gases, and various chemical resi-
dues, with MDA and 4-HDA being the majority. -erefore,
the concentration of MDA+4-HDA is an indicator of the































Figure 8: Average pre-post steatosis by study groups. Group 1: animals that maintained a steatotic diet and received concomitant treatment.
Group 2: animals that maintained a steatotic diet and received no drug. Group 3: animals that did not continue with the steatotic diet but



































Figure 9: Percentage of average pre-post steatosis (program) by study groups. Group 1: animals that maintained a steatotic diet and received
concomitant treatment. Group 2: animals that maintained a steatotic diet and received no drug. Group 3: animals that did not continue with the


























Figure 10: Percentage of average pre-post steatosis (program) by study groups. Group 1: animals that maintained a steatotic diet and
received concomitant treatment. Group 2: animals that maintained a steatotic diet and received no drug. Group 3: animals that did not
continue with the steatotic diet but received melatonin treatment. Group 4: animals that did not continue with the steatotic diet and did not
receive any drug.
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In our study, we found that both MDA and carbonyls
decreased in the groups that were administered melatonin
with respect to those who did not receive it; therefore, this
indicates an effect of the hormone on lipid metabolism at the
intracellular level.
Plasma levels of cholesterol and triglycerides increased in
animals subjected to steatogenic diet but were not modified
by the effect of melatonin with statistical significance.
However, we can observe that animals that continue with the
diet and take melatonin (group 1) exhibit lowered LDL and
























































Figure 12: Average pre-post MDA by study groups. Group 1: animals that maintained a steatotic diet and received concomitant treatment.
Group 2: animals that maintained a steatotic diet and received no drug. Group 3: animals that did not continue with the steatotic diet but









































Figure 13: Medium pre-post carbonyls by study groups. Group 1: animals that maintained a steatotic diet and received concomitant
treatment. Group 2: animals that maintained a steatotic diet and received no drug. Group 3: animals that did not continue with the steatotic
diet but received melatonin treatment. Group 4: animals that did not continue with the steatotic diet and did not receive any drug.
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cholesterol levels and increased HDL levels. -is could
indicate some protective effect of melatonin in this group of
animals, although it lacks statistical significance. In the
literature, we find works that ratify the lipid-lowering effect
of melatonin [22, 24, 28, 42, 43]. One reason that might
argue this result is that, in our experimental model, we start
from established hepatic steatosis, with chronically elevated
blood lipid levels, a situation that does not occur in the other
experimental studies, since melatonin is administered
concomitantly with the administration of the high-fat diet as
prevention.
With respect to the levels of liver enzymes (ALT and
GGT), bilirubin, and FA, in our study, their levels have not
been altered by the action of melatonin. In other experi-
mental studies onmurine models, Pan et al. [20] were able to
demonstrate that the administration of intraperitoneal
melatonin at doses of 5 to 10mg/kg/day for 12 days was
effective in reducing serum ALT and AST. -e difference
with our work is that the previous authors gave jointly the
steatotic diet and melatonin to the experimental animals and
our work starts from animals with an already established
NAFLD; that is to say, perhaps melatonin could not have a
preventive effect of the hepatic lesion when it is administered
early (before the accumulation of fat in the hepatocyte),
being its effect null when NAFLD is already established.
-e work carried out by Hatzis et al. [21] gives us some
light in this respect. -e authors were able to demonstrate
that hepatic cell necrosis was significantly lower in rats that
had received a diet rich in fats and melatonin at doses of
5mg or 10mg/kg/day via intraperitoneal for 4–8 weeks,
finding that the levels of AST and ALT were lower after
receiving the drug. However, in their work, a group of
animals underwent induced steatosis (through diet) before
being treated with melatonin, because this last group of
animals did not obtain any hepatic cytoprotective effect, like
the animals in our study. It can be concluded that melatonin
is ineffective as a treatment once NAFLD is established. In
our work, the degrees of NAFLD reached after the diet were
very high, much more than those obtained in similar studies
with other experimental models; perhaps with more mod-
erate degrees of fat infiltration, melatonin could have some
effect, and this extreme should be investigated.
-e traditional method of evaluation of the degree of
hepatic steatosis, used by most authors in the world, is
performed by evaluating the histological sample stained with
Hematoxylin-Eosin evaluation performed more or less
subjectively by a pathologist. To avoid subjectivity and
improve accuracy, we also use a method of evaluation by
digital image analysis through a program created by the team
itself, to contrast this subjectivity. In our study, it was ob-
served that the measurement of steatosis by digital analysis
provides in all cases some average values lower than those
obtained by the direct vision of the pathologist. Studies
published in the literature corroborate this overestimation
[44]. An explanation of this overestimation, as several au-
thors explain, is that the measured area of hepatocyte
vacuoles is better measured by computer methods than the
purely visual way, since the computer is capable of elimi-
nating areas of the sample with a similar visual aspect (in the
design of our computer program, we took this fact into
account). In our study, the percentage change of steatosis
between the pretime and posttime of subject tracking shows
a strong linear relationship between the two methods. In
conclusion, in our study, we obtained a high correlation
between both methods, but with an overestimation of the
degree of steatosis by the pathologist analysis.
In our study, melatonin was unable to restore histology,
not even to the low steatosis figures at baseline, although we
observed the phenomenon that the degree of fat infiltration,
which increased gradually if the animals continued to take
the steatotic diet, remained stable if they were given mel-
atonin, with significant differences. -ese data corroborate
experimental data in murine models. Hatzis et al. [21]
demonstrated a protective effect of melatonin when ad-
ministered synchronously with a high-fat diet; however, this
effect could not be demonstrated in the group of rats that
received melatonin at a late stage of the experiment, i.e., as a
treatment once hepatic steatosis was established. Pan et al.
[20] also showed that a moderate or high dose of melatonin
(5–10mg/kg/day) improved the degree of hepatic steatosis
when administered concomitantly to the high-fat diet.
Human studies have the handicap that they do not
perform biopsies to corroborate the improvement of hepatic
steatosis after the administration of melatonin, probably
because of the not inconsiderable percentage of complica-
tions that this diagnostic method entails.
With this work, we can demonstrate a protective effect of
melatonin in terms of the lower progression of steatosis in
the histological sample; however, we cannot show im-
provement, as in other studies. We also discovered a
hypolipidemic effect of melatonin, since animals that
maintain the steatotic diet and take melatonin reduce their
levels of total and LDL cholesterol whilst increasing their
levels of HDL cholesterol, although these results are not
statistically significant. As previously stated, in our work, we
start from very high levels of steatosis. Rodents in the ex-
perimental studies were administered melatonin concomi-
tantly with the fat-rich diet, so these studies aim to find a
protective effect of melatonin in the establishment of hepatic
steatosis, not the reversal of hepatic steatosis, which is the
aim of our study. On the other hand, in studies carried out in
humans, the degree of steatosis from which we start does not
reach the very high levels of steatosis from which we start. It
is, therefore, possible that melatonin has a preventive effect
on liver injury or even serves as a treatment for hepatic
steatosis when the degree of fat involvement of hepatocytes
is lower, being difficult to reverse when the hepatocyte in-
volvement is the majority and does not cease the stimulus
that produced it.
Another aspect to keep in mind is the melatonin ad-
ministration time. We have seen that in our study positive
results are obtained at the molecular level, in the intimate
mechanism of production of NAFLD; that is to say, we
observe that melatonin attenuates oxidative stress and lipid
peroxidation in groups of animals that continue with the
diet; however, the changes at a histological level have only
been demonstrated at the time of preventing progression.
-is could be because the period of administration of
10 Canadian Journal of Gastroenterology and Hepatology
melatonin (4 weeks) or the dose administered (10mg/kg/
day) is insufficient to observe changes in the accumulation of
hepatocyte lipids at the histological level. Studies with a
longer administration time of melatonin or with a higher
dose would be needed to demonstrate this effect.
We believe that one of the greatest strengths of our study
was the experimental model used. It is original from our
group who are experienced in another work [45]. In addi-
tion, we tried to individualize the effect of melatonin from
the effect of the intake of the steatotic diet. Many of the
papers do not include groups with discontinuation of the
diet or seek purely the protective effect of the drug ad-
ministered in conjunction with the diet. In our work, we
preferred to use 4 different groups of animals, which forced
us to use a considerable number of experimental animals but
allowed us to simulate the different scenarios in which
melatonin can be administered as a drug to treat NAFLD.
Data Availability
-e data used to support this study are provided in the
Supplementary Materials. -e complementary data can be
obtained from the corresponding author upon request.
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